472 related articles for article (PubMed ID: 12918586)
1. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
[TBL] [Abstract][Full Text] [Related]
2. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Ushiyama C; Osada S; Inoue T; Shimada N; Koide H
J Diabetes Complications; 2003; 17(6):349-54. PubMed ID: 14583180
[TBL] [Abstract][Full Text] [Related]
3. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis.
Utsumi K; Kawabe M; Hirama A; Ueda K; Kamada Y; Arii K; Komaba Y; Katsura K; Iino Y; Katayama Y
Clin Chim Acta; 2007 Feb; 377(1-2):198-200. PubMed ID: 17126824
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
5. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
Morimoto S; Yano Y; Maki K; Sawada K; Iwasaka T
Am J Nephrol; 2007; 27(6):643-8. PubMed ID: 17878713
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis.
Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Halvorsen B; Ose L; Aukrust P; Holven KB
Cytokine; 2013 Jan; 61(1):194-8. PubMed ID: 23131422
[TBL] [Abstract][Full Text] [Related]
8. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
9. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes.
Kadoglou NP; Vrabas IS; Sailer N; Kapelouzou A; Fotiadis G; Noussios G; Karayannacos PE; Angelopoulou N
Diabetes Metab; 2010 Apr; 36(2):144-51. PubMed ID: 20149706
[TBL] [Abstract][Full Text] [Related]
10. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
Jacqueminet S; Ben Abdesselam O; Chapman MJ; Nicolay N; Foglietti MJ; Grimaldi A; Beaudeux JL
Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of matrix metalloproteinase-9/tissue inhibitors of matrix metalloproteinase -1 imbalance in maternal serum, amniotic fluid, umbilical cord serum in patients with premature rupture of the membranes].
Lu D; Wang ZX; Wang XL; Gu XW; Wang YX; Fu D
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):20-4. PubMed ID: 16635322
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
14. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
15. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
[TBL] [Abstract][Full Text] [Related]
17. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
18. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
20. [Changes of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in the bronchoalveolar lavage fluid and the serum of patients with idiopathic pulmonary fibrosis].
Wei LQ; Li ZH; Kang J; Hou XM; Yu RJ
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):399-402. PubMed ID: 17045024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
